|
Sanchez-Villalobos M, Campos Banos E, Juan Fita MJ, Egea Mellado JM, Gonzalez Gallego I, Beltran Videla A, Berenguer Piqueras M, Bermudez Cortes M, Moraleda Jimenez JM, Guillen Navarro E, Salido Fierrez E, Perez-Oliva AB. A Newborn Screening Program for Sickle Cell Disease in Murcia (Spain). Int J Neonatal Screen. 2023 Oct 10;9(4):55. doi: 10.3390/ijns9040055. PubMed PMID: 37873846; PubMed Central PMCID: PMC10594431.
AÑO: 2023; IF: 3.5
|
37873846
|
Liarte S, Bernabe-Garcia A, Rodriguez-Valiente M, Moraleda JM, Castellanos G, Nicolas FJ. Amniotic Membrane Restores Chronic Wound Features to Normal in a Keratinocyte TGF-beta-Chronified Cell Model. Int J Mol Sci. 2023 Mar 25;24(7):6210. doi: 10.3390/ijms24076210. PubMed PMID: 37047181; PubMed Central PMCID: PMC10094701.
AÑO: 2023; IF: 4.9
|
|
Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N, Arroyo CH, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson KMO, Bourhis JH, Mateos MV, Rabin N, Jost E, Kroger N, Moraleda JM, Za T, Hayden PJ, Beksac M, Mclornan D, Schonland S, Manier S. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023 Nov;58(11):1182-1188. doi: 10.1038/s41409-023-02048-7. Epub 2023 Aug 5. PubMed PMID: 37543712; PubMed Central PMCID: PMC10622318.
AÑO: 2023; IF: 4.5
|
|
Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera JL, Lopez-Corral L, Martin-Antonio B, Zabaleta A, Inoges S, Varea S, Rosinol L, Lopez-Diaz de Cerio A, Tovar N, Jimenez R, Lopez-Parra M, Rodriguez-Lobato LG, Sanchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Perez-Simon JA, Paiva B, Prosper F, Saez-Penataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernandez de Larrea C. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. PubMed PMID: 37414060.
AÑO: 2023; IF: 41.6
|
|
Fernandez-Santos ME, Garcia-Arranz M, Andreu EJ, Garcia-Hernandez AM, Lopez-Parra M, Villaron E, Sepulveda P, Fernandez-Aviles F, Garcia-Olmo D, Prosper F, Sanchez-Guijo F, Moraleda JM, Zapata AG. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Front Immunol. 2022 Jun 9;13:918565. doi: 10.3389/fimmu.2022.918565. eCollection 2022. PubMed PMID: 35812460; PubMed Central PMCID: PMC9261977.
AÑO: 2022; IF: 7.3
|